Literature DB >> 16532973

The role of inhaled long-acting beta-2 agonists in the management of asthma.

H William Kelly1, Michelle S Harkins, Homer Boushey.   

Abstract

The role of inhaled beta-2 agonists in the management of asthma has changed significantly over the last several years. This review outlines the most recent understanding of the pathophysiology of asthma and the studies that define the roles that both short- and long-acting beta-2 agonists play in therapy for this disease. A concentration on the clinical pharmacology and genetic implications for clinical use of this class of drugs in accordance with the national and international guidelines are described.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16532973      PMCID: PMC2594808     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  55 in total

Review 1.  Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation.

Authors:  G P Anderson
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

Review 2.  Asthma. From bronchoconstriction to airways inflammation and remodeling.

Authors:  J Bousquet; P K Jeffery; W W Busse; M Johnson; A M Vignola
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

3.  Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration.

Authors:  B J Lipworth; I Aziz
Journal:  Chest       Date:  2000-01       Impact factor: 9.410

4.  Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma.

Authors:  D Bouros; N Bachlitzanakis; J Kottakis; P Pfister; V Polychronopoulos; E Papadakis; S Constantopoulos; M Froudarakis; L Sichletidis; N Siafakas
Journal:  Eur Respir J       Date:  1999-09       Impact factor: 16.671

5.  Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework.

Authors:  S M Dennis; S J Sharp; M R Vickers; C D Frost; G K Crompton; P J Barnes; T H Lee
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

6.  Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.

Authors:  W Busse; H Nelson; J Wolfe; C Kalberg; S W Yancey; K A Rickard
Journal:  J Allergy Clin Immunol       Date:  1999-06       Impact factor: 10.793

7.  Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.

Authors:  R R Rosenthal; W W Busse; J P Kemp; J W Baker; C Kalberg; A Emmett; K A Rickard
Journal:  Chest       Date:  1999-09       Impact factor: 9.410

8.  Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.

Authors:  A R Guhan; S Cooper; J Oborne; S Lewis; J Bennett; A E Tattersfield
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

9.  Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

Authors:  S Shrewsbury; S Pyke; M Britton
Journal:  BMJ       Date:  2000-05-20

10.  Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroids.

Authors:  J S Kelloway; R Wyatt; J DeMarco; S Adlis
Journal:  Ann Allergy Asthma Immunol       Date:  2000-03       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.